Meilin Liao
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Proteomics-based characterization of apigenin-mediated anti-inflammatory effects in TNF-α-stimulated ARPE-19 cells.
Journal: International immunopharmacology
Published: April 02, 2026
Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
Journal: EBioMedicine
Published: January 22, 2019
Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 01, 2016
Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression.
Journal: Oncotarget
Published: October 12, 2016
Guideline for diagnosis and treatment of ALK positive non-small cell lung cancer in China
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: December 26, 2015
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 06, 2015
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Journal: Japanese journal of clinical oncology
Published: November 18, 2014
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 08, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 03, 2014
Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: March 04, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Journal: The Lancet. Oncology
Published: January 14, 2014
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Journal: The Lancet. Oncology
Published: June 21, 2013
Last Updated: 09/26/2026